 | |
 Lonza Tower in Basel, Switzerland | |
| Company type | Aktiengesellschaft |
|---|---|
| ISIN | CH0013841017  |
| Industry | |
| Founded | 1897 |
| Headquarters | Basel, Switzerland |
Key people |
|
| Products | Biopharmaceuticals |
| Revenue |  CHF 6.72 billion (2023)[1] |
 CHF 880 million (2023)[1] | |
| CHF 655 million (2023)[1] | |
| Total assets | CHF 16.8 billion (2023)[1] |
| Total equity | CHF 9.51 billion (2023)[1] |
Number of employees | 18,000 (2023)[1] |
| Website | lonza |
Lonza Group AG is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector.